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Context:MEN1 gene alterations have been implicated in lung carcinoids, but their effect on gene
expression and disease outcome is unknown.
Objective: Our objective was to analyze MEN1 gene and expression anomalies in lung neuroen-
docrine neoplasms and their correlations with clinicopathologic data and disease outcome.
Design: We examined 74 lung neuroendocrine neoplasms including 58 carcinoids and 16 high-
gradeneuroendocrine carcinomas (HGNECs) forMEN1mutations (n70) andallelic losses (n69),
promoter hypermethylation (n 65), andmRNA (n 74) expression. Results were correlatedwith
disease outcome.
Results:MEN1mutationswere found in 7of 55 (13%) carcinoids and in 1HGNEC,mostly associated
with loss of the second allele.MEN1 decreased expression levels correlated with the presence of
mutations (P .0060) andwas also lower inHGNECs than carcinoids (P .0024).MEN1methylation
was not associated with mRNA expression levels. Patients with carcinoids harboringMEN1muta-
tion and loss had shorter overall survival (P .039 and P .035, respectively) and lowMEN1mRNA
levels correlatedwithdistantmetastasis (P .00010)andshorter survival (P .0071). Inmultivariate
analysis, stage andMEN1 allelic loss were independent predictors of prognosis.
Conclusion: Thirteen percent of pulmonary carcinoids harbor MEN1 mutation associated with
reducedmRNAexpression and poor prognosis. Also inmutation-negative tumors, lowMEN1 gene
expression correlates with an adverse disease outcome. Hypermethylation was excluded as the
underlying mechanism. (J Clin Endocrinol Metab 99: E374–E378, 2014)
Pulmonary neuroendocrine neoplasms (NENs) includewell-differentiated carcinoids, classified into typical
carcinoid (TC) and atypical carcinoid (AC) subtypes, with
a relatively favorableprognosis (1, 2), andaggressivehigh-
grade neuroendocrine carcinomas (HGNECs), ie, large-
cell neuroendocrine carcinoma (LCNEC) and small-cell
lung cancer (SCLC).
Lung carcinoids occur in 5% of patients with multiple
endocrine neoplasia (MEN) type 1 syndromewithMEN1
germline mutations (3). MEN1 mutations have been re-
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ported in approximately 16% of sporadic lung carcinoids
(4–6) but are exceptional inHGNECs (7, 8). Allelic losses
of theMEN1 locus are detected more frequently (36%)
than genemutations (5), suggesting that alternativemech-
anisms might lead toMEN1 gene inactivation. So far, the
association of MEN1 gene alterations with clinical fol-
low-up has not been reported in lung NENs.
Here we report a comprehensive analysis ofMEN1 al-
terations, methylation status, and transcriptional expres-
sion in 74 lung NENs. Results are compared with tumor
characteristics and clinical outcome.
Materials and Methods
Tissue samples
Seventy-four sporadic lung NENs (34 TCs, 23 ACs, 1 un-
classified carcinoid, 9 LCNECs, 6 SCLCs, and 1mixed LCNEC-
SCLC), including 71 with follow-up (median 52 months), were
studied. Institutional review board approval for the study was
obtained by each contributing center following local ethical re-
quirements. Nine neuroendocrine cell lines were included for
MEN1 mRNA expression analysis.
MEN1 mutational analysis
The entire coding region and splice junctions ofMEN1were
analyzed on tumor and matched normal DNA by Sanger se-
quencing, as described (9) (Supplemental Table 1A).
MEN1 deletion analysis
Fluorescent in situ hybridization on frozen sections was
performed using the MEN1 locus BAC probe CTD-222019,
and centromere probes for chromosomes 1, 11, 3, and 7 as
described (10).
Quantitative real-time PCR
Quantitative real-time PCR was performed using mRNA on
MEN1, menin interactors JUND and MLL, and menin targets
HOXC8,P18,P21, andP27, using primers listed in Supplemen-
tal Table 1B. Expression levels were normalized to ACTB and
CYPA housekeeping genes as described (11).
Methylation-specific PCR and next-generation
sequencing
MEN1 promoter methylation analysis was performed on all
cases by nested methylation-specific PCR (MSP) (Supplemental
Table 1C) and by next-generation sequencing (NGS) onmethyl-
CpG binding domain-immunoprecipitated DNA of 10 primary
carcinoids and carcinoid cell lines NCI-H720 and NCI-H727
(focusing on theMEN1 gene).
Statistical analysis
Correlations betweenMEN1 data and follow-up were deter-
minedusing IBMSPSSStatistics (version20.0.0; IBM) setting the
P values cutoff for significance at .05. Differences in mean
MEN1mRNA levelswere determined by Student’s t test, and the
optimal cutoff point was determined using area under the re-
ceiver operating characteristic curve analysis. Associations be-
tween clinical and molecular parameters were calculated using
logistic and linear regression, Fisher’s exact, or 2 tests, as ap-
propriate. Associations between relative expression levels of
MEN1 and other genes were calculated using Pearson’s
correlation.
Survival curves were created by the Kaplan-Meier method
and compared using the log-rank test. The prognostic value of
age at diagnosis, histopathology, sex, smoking status, tumor di-
ameter, and MEN1 mutation, deletion, and gene expression
were tested in univariate and multivariate settings using Cox
regression. Only variables with a P value  .10 in univariate
analyses were included in multivariate analyses.
Results
MEN1 gene mutations and deletions are more
frequent in ACs
MEN1mutations were searched in 70 tumors, includ-
ing 7 previously published cases (5). Eight cases (11%)
showed nonsynonymous somatic alterations: 2 of 32 TCs
(6%), 5 of 23 ACs (22%), and 1 of 7 LCNECs (14%).
Mutations included 3 small deletions, 3 single-nucleotide
substitutions, and2 insertions (SupplementalTables 2and
3). Patient 35 showed the same MEN1 mutations in the
primary tumor and 2 distantmetastases removed 8 and 10
years later.
Ploidy status andMEN1 deletionwere analyzed by flu-
orescent in situ hybridization in 69 tumors (Table 1 and
Figure 1, A–C). Most carcinoids were disomic, whereas
HGNECs were more frequently polysomic. Among car-
cinoids, 8 of 57 (14%, 1 TC and 7 ACs) showed MEN1
allelic loss. In HGNECs, MEN1 was deleted in 3 of 12
cases (25%). MEN1 deletion was more frequent in ACs
than in TCs (P .0060) and was significantly associated
with the presence of mutations in both the total group of
NENs (P  .0022) and in carcinoids (P  .0063) (Sup-
plemental Table 3).
MEN1 gene expression is heterogeneous in lung
NENs
Quantitative RT-PCR performed on all 74 NENs
showed that relative MEN1 expression levels in lung
NENs ranged from 0.031 to 0.85, generally lower than
exocrine pancreas (mean 0.58; Figure 1D) but higher
than normal lung (mean 0.078). A gradual decrease in
meanMEN1 expression values was apparent fromTCs to
ACs and HGNECs (Figure 1, D and E). Similarly,MEN1
expression levels in SCLC NCI-H69 and LCNEC NCI-
H460 cell lines were lower than in lung carcinoid NCI-
H720 and NCI-H727 cells (Figure 1D). MEN1 gene ex-
pression levels were inversely correlated to the presence of
mutations and deletions (Supplemental Table 3) in the
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complete group of lungNENs (P .0060) and carcinoids
(P  .025).
No correlation between MEN1 methylation and
gene expression
Because low MEN1 expression levels were present in
tumors with neitherMEN1mutation nor deletion, we an-
alyzed MEN1 promoter methylation by MSP. No meth-
ylation-specific productwas seen in65primaryNENs, cell
lines, and 15 normal lungs from noncancer patients. NGS
in10primary carcinoids and lung carcinoid cell linesNCI-
H720andNCI-H727 showed somemethylation signals in
MEN1promoter region andgenebodybut not at the locus
used forMSP analysis (Supplemental Figure 1). No meth-
ylation signals were found in CpG islands. There were no
differences inmethylation between samples with high and
lowMEN1 mRNA levels.
Deregulation of MEN1 is associated with
metastatic disease and poor prognosis
MEN1 gene mutations and deletions and decreased
gene expression were associated with the presence of
distant metastasis in both the total group of NENs and
the carcinoids subgroup but were not related to sex,
age, and smoking status (Supplemental Table 4). In par-
ticular, MEN1 mRNA levels were significantly lower
in patients with distant metastasis and/or patients who
died from their tumor, both in the entire group (0.162 vs
0.318, P  .00080) and within the carcinoid subgroup
(Figure 1E).
Univariate survival analysis showed in both the com-
plete group ofNENs and the carcinoid subgroup that age,
histopathology, stage, presence of MEN1 deletions, and
decreased gene expression were significantly associated
with higher risk of death (Table 1). At multivariate sur-
vival analysis, histopathology and decreasedMEN1 gene
expression in lung NENs overall and stage and MEN1
deletion in the carcinoid subgroup retained statistical sig-
nificance. Kaplan-Meier survival analysis confirmed that
the 15-year overall survival of lung carcinoids was signif-
icantly shorter in patients with MEN1 mutation (Figure
1F), decreased mRNA levels (Figure 1G), and deletion
(P  .035).
Menin interactors and target genes
Within the complete set of NENs,MEN1 gene expres-
sionwas correlatedwith that of its interactors JUND (P
.016) andMLL (P .026) but not of its targetsHOXC8,
P18, P21, and P27. Significant associations between
MEN1 deletion and low HOXC8 expression (P  .010)
and low P18 gene expression (P .017) were also found.
MEN1 mutational status and menin protein expression
were not associated with mRNA levels of interactors and
downstream targets.
In the complete group of NENs, as well as within car-
cinoids, lower levels ofP18 expression (P .0074andP
.0011, respectively) were associated with lower 15-year
survival.
Discussion
Our studyonpulmonaryNENs shows that the presence of
MEN1mutation and/or a lowerMEN1 gene expression is
associated with distant metastasis and lower 15-year sur-
vival in both the entire cohort of NENs and lung carci-
noids considered separately.
MEN1 mutations were found in 13% of carcinoids (7
of 55), in line with previous reports (4, 5), with most mu-
tations occurring in ACs. All mutations were of the loss-
of-function type, and most mutated cases also displayed
deletion of the second MEN1 locus. Only 1 of 15
HGNECswasmutated, confirming thatMEN1mutations
do not play a major role in HGNECs (7, 8).
Table 1. Univariate and Multivariate Analysis of Clinical Data and MEN1 Parameters Correlated With Outcome of
Patients With Pulmonary NENs
Lung NENs, P Values Carcinoids, P Values
Univariate Multivariatea Univariate Multivariatea
Age at diagnosis .0003 NS .0021 NS
Diameter .086 NI NS NI
Histopathology .0001 .0001 .011 NS
Sex .049 NS NS NI
Smoking status NS NI NS NI
Stage .0002 NS .0013 .0009
MEN1 deletion .013 NS .047 .013
MEN1 mutation .060 NI .050 NI
MEN1 gene expression .0068 .017 .035 NS
Abbreviations: NI, not included in multivariate analysis; NS, not significant.
a Only parameters displaying a P value  .05 are included in multivariate analysis, and in the final model all P values needed to be .05.
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The large majority of neoplasms with the wild-type
MEN1 gene had high mRNA levels. However, not all
cases with low mRNA levels harbored mutations or
deletions, indicating that other mechanisms might un-
balance MEN1 expression in these tumors. No hyper-
methylation was seen in CpG islands within theMEN1
promoterwithMSP analysis, whereas
methylated regions outside the CpG
island were identified by methyl-CpG
binding domain sequencing. How-
ever, suchmethylation was not asso-
ciated with reduced MEN1 mRNA
levels, suggesting thatMEN1 hyper-
methylationunlikely underliesMEN1
downregulation.
MEN1 gene alterations and re-
duced expression were significantly
associated with tumor stage, pres-
ence of distant metastases, and pa-
tient survival. At multivariate analy-
sis, decreasedMEN1 gene expression
was an independent predictor of dis-
ease outcome in both the complete
group of NENs and in the group
of carcinoids alone. This finding
seems specific for lung NENs be-
cause it is not observed in pancre-
atic NENs (10).
The mechanisms underlying the
role of MEN1 gene loss of function
and the acquisitionof clinical aggres-
siveness in lung carcinoids deserves
further investigation. We identified
correlations between MEN1 and
JUND/MLL mRNA levels but not
with menin targets P18, P21, and
P27, suggesting that lung-specific
mechanisms might be active, such
as the E-cadherin/-catenin path-
way, which interacts with menin
and is frequently deregulated in
lung NENs (7).
In conclusion, our comprehen-
sive overview of MEN1 molecular
alterations in lung NENs demon-
strates a significant association be-
tween MEN1 gene deregulation
and clinical aggressiveness in lung
carcinoids and postulates different
mechanisms of gene regulation in
well-differentiated and poorly dif-
ferentiated NENs.
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